181 related articles for article (PubMed ID: 9499082)
1. Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design.
Thomson SA; Burrows SR; Misko IS; Moss DJ; Coupar BE; Khanna R
J Virol; 1998 Mar; 72(3):2246-52. PubMed ID: 9499082
[TBL] [Abstract][Full Text] [Related]
2. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells.
Bonini C; Lee SP; Riddell SR; Greenberg PD
J Immunol; 2001 Apr; 166(8):5250-7. PubMed ID: 11290810
[TBL] [Abstract][Full Text] [Related]
3. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.
Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR
J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775
[TBL] [Abstract][Full Text] [Related]
4. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells.
Taylor GS; Long HM; Haigh TA; Larsen M; Brooks J; Rickinson AB
J Immunol; 2006 Sep; 177(6):3746-56. PubMed ID: 16951335
[TBL] [Abstract][Full Text] [Related]
5. CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting.
Rodriguez F; Harkins S; Redwine JM; de Pereda JM; Whitton JL
J Virol; 2001 Nov; 75(21):10421-30. PubMed ID: 11581410
[TBL] [Abstract][Full Text] [Related]
6. Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells.
Rowell JF; Ruff AL; Guarnieri FG; Staveley-O'Carroll K; Lin X; Tang J; August JT; Siliciano RF
J Immunol; 1995 Aug; 155(4):1818-28. PubMed ID: 7636236
[TBL] [Abstract][Full Text] [Related]
7. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
[TBL] [Abstract][Full Text] [Related]
8. Design and evaluation of optimized artificial HIV-1 poly-T cell-epitope immunogens.
Reguzova A; Antonets D; Karpenko L; Ilyichev A; Maksyutov R; Bazhan S
PLoS One; 2015; 10(3):e0116412. PubMed ID: 25786238
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II.
SenGupta D; Norris PJ; Suscovich TJ; Hassan-Zahraee M; Moffett HF; Trocha A; Draenert R; Goulder PJ; Binder RJ; Levey DL; Walker BD; Srivastava PK; Brander C
J Immunol; 2004 Aug; 173(3):1987-93. PubMed ID: 15265933
[TBL] [Abstract][Full Text] [Related]
10. Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways.
Thiele F; Tao S; Zhang Y; Muschaweckh A; Zollmann T; Protzer U; Abele R; Drexler I
J Virol; 2015 Mar; 89(5):2698-709. PubMed ID: 25520512
[TBL] [Abstract][Full Text] [Related]
11. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
12. Exogenous, TAP-independent lysosomal presentation of a respiratory syncytial virus CTL epitope.
Johnstone C; Ramos M; García-Barreno B; López D; Melero JA; Del Val M
Immunol Cell Biol; 2012 Nov; 90(10):978-82. PubMed ID: 22929180
[TBL] [Abstract][Full Text] [Related]
13. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
14. Vaccinia Virus Vectors Targeting Peptides for MHC Class II Presentation to CD4
Hobbs SJ; Harbour JC; Yates PA; Ortiz D; Landfear SM; Nolz JC
Immunohorizons; 2020 Jan; 4(1):1-13. PubMed ID: 31896555
[TBL] [Abstract][Full Text] [Related]
15. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design.
Thomson SA; Khanna R; Gardner J; Burrows SR; Coupar B; Moss DJ; Suhrbier A
Proc Natl Acad Sci U S A; 1995 Jun; 92(13):5845-9. PubMed ID: 7541138
[TBL] [Abstract][Full Text] [Related]
16. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
Khanna R; Burrows SR; Kurilla MG; Jacob CA; Misko IS; Sculley TB; Kieff E; Moss DJ
J Exp Med; 1992 Jul; 176(1):169-76. PubMed ID: 1377222
[TBL] [Abstract][Full Text] [Related]
17. Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming.
Schlecht G; Loucka J; Najar H; Sebo P; Leclerc C
J Immunol; 2004 Nov; 173(10):6089-97. PubMed ID: 15528345
[TBL] [Abstract][Full Text] [Related]
18. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
[TBL] [Abstract][Full Text] [Related]
19. Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones.
Wallace LE; Wright J; Ulaeto DO; Morgan AJ; Rickinson AB
J Virol; 1991 Jul; 65(7):3821-8. PubMed ID: 1710291
[TBL] [Abstract][Full Text] [Related]
20. Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies.
Viehl CT; Frey DM; Phommaly C; Chen T; Fleming TP; Gillanders WE; Eberlein TJ; Goedegebuure PS
Breast Cancer Res Treat; 2008 May; 109(2):305-14. PubMed ID: 17653857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
